Fungoid Af

Showing Topics 1 - 4 of 4. RSS Feed

 Fungoid AF Undecylenic Acid, Undecylenate Salts, Zincundecate

Undecylenic acid is an organic compound with the formula CH2=CH(CH2)8CO2H. It is an unsaturated fatty acid. It is a colorless oil. Undecylenic acid is mainly used for the production of Nylon-11 and in the treatment of fungal infections of the skin, but it is also a precursor in the manufacture of many pharmaceuticals, personal hygiene products, cosmetics, and perfumes.[1] Salts and esters of undecylenic acid are known as undecylenates. Contents 1 Preparation 2 General co...
mycosis fungoides

A neighbor died after reaching the tumor stage. ## A neighbor struggled with Mycosis Fungoides a lymphoma and after initial treatment stopped going to oncologists. He reached the tumor stage and died. He said at one point he was treating the plaques with epsom salt. ## Yes, epsom salt would only be a topical treatment and it's not proven to help with such a condition, anyway. This is a T-cell lymphoma, so that means he wasn't doing anything to help with the internal source of the problem. Are there any other questions or concerns? ## There needs to be scientific help for Lupus and drugs to cure the disease and not just a band-aid approach. There is no real diagnostic for lupus. ...

Updated in Antifungal
 Poteligeo Mogamulizumab-kpkc

Mogamulizumab (trade name Poteligeo)[1] is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[2] The US FDA approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.[3] It was approved in Japan in 2012 for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014 for relapsed or refractory CCR4+ cutaneous T cell lympho...
 Mogamulizumab

Mogamulizumab (trade name Poteligeo)[1] is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4).[2] The US FDA approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.[3] It was approved in Japan in 2012 for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma (ATCLL) and in 2014 for relapsed or refractory CCR4+ cutaneous T cell lympho...


Can't Find What You're Looking For? Submit a New Topic Below

No registration needed.
Simply fill out the form below.

 *
What are the main keywords of your topic?


 *

 *


 Optional, stays hidden.
Get notified when a reply is posted here.




5) Text Verification: *
Prevents SPAM.

Click here to show the question



This form will be submitted securely


TRUSTe

Discussion Thread Guidelines: Any participation in the discussion threads signifies your agreement with the Terms of Use and Privacy Policy. (1) Act civilized and be respectful towards others. No profanity, vulgarity or lewd / suggestive content is allowed. (2) Posts encouraging, facilitating, or seeking advice about the abuse of medications or other substances are prohibited. (3) Personal contact information (such as telephone numbers, email addresses, etc) is not allowed to appear on our discussion threads. (4) We do not allow our forums to be used for buying, selling, trading, or for the promotion of a product or service. (5) Posting external links to other web sites is not allowed without our prior approval. (6) We reserve the right to edit or remove content which we find objectionable to the community at our sole discretion.



Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 February 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA